Prognostic value of the systemic immune-inflammation index in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.

BACKGROUND

Although the systemic immune-inflammation index (SII) has emerged as a potential prognostic marker in various cancers, its specific role in non-small cell lung cancer (NSCLC) patients undergoing immunotherapy remains insufficiently explored. To address this critical gap, we conducted a comprehensive meta-analysis to assess the prognostic value of SII in NSCLC patients treated with immune checkpoint inhibitors (ICIs).

METHOD

A comprehensive search was conducted across multiple databases-including PubMed, EMBASE, Cochrane and Web of Science-to identify relevant studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to evaluate the prognostic significance of SII for survival outcomes.

RESULT

Ten studies involving a total of 1,547 patients were included. High systemic immune-inflammation index (SII) was significantly associated with worse overall survival (OS) (HR=1.44, 95% CI=1.21-1.70, p < 0.001; I²=3.8%) and progression-free survival (PFS) (HR=1.44, 95% CI=1.21-1.71, p < 0.001; I²=37.2%). Subgroup analysis indicated that an SII >792 was significantly associated with poorer OS and PFS.

CONCLUSION

High SII is significantly associated with poorer OS and PFS, particularly when SII >792.

SYSTEMATIC REVIEW REGISTRATION

https://www.crd.york.ac.uk/PROSPERO/view/CRD42024586791, identifier RD42024586791.